Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rucaparib and Atezolizumab in Advanced Gynecologic Cancers and TNBC
NCT03101280Phase 1Completed
- Sponsor
- Roche
- Start
- Apr 2017
- Primary completion
- Aug 2020
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of rucaparib and atezolizumab in ovarian cancer, endometrial cancer (EC) and triple-negative breast cancer (TNBC) (3 arms), sponsored by Roche. Primary endpoints: Percentage of Participants With Adverse Events at 45 months, Percentage of Participants With Dose-Limiting Toxicities and 1 more. Started Apr 2017; status: completed.
02
Drugs
rucaparibatezolizumab
03
Conditions
ovarian cancerendometrial cancer (EC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03101280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03101280.